APO Research
Talk to an analyst

APO RESEARCH · REPORT

Haemophilus b Conjugate Vaccine (Hib)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Haemophilus b Conjugate Vaccine (Hib) Market Outlook and Growth Opportunities 2026

19 December 2025196 pages

Choose your research edition.

Industry ResearchHaemophilus b Conjugate Vaccine (Hib) Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Haemophilus b Conjugate Vaccine (Hib) Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal Haemophilus b Conjugate Vaccine (Hib) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Haemophilus b Conjugate Vaccine (Hib) Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Haemophilus b Conjugate Vaccine (Hib) Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Haemophilus b Conjugate Vaccine (Hib) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Haemophilus b Conjugate Vaccine (Hib) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Haemophilus b Conjugate Vaccine (Hib) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Haemophilus b Conjugate Vaccine (Hib) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Haemophilus b Conjugate Vaccine (Hib) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Haemophilus b Conjugate Vaccine (Hib) market include Merck, GSK and Sanofi Pasteur, SA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Haemophilus b Conjugate Vaccine (Hib) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Haemophilus b Conjugate Vaccine (Hib) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Haemophilus b Conjugate Vaccine (Hib) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Haemophilus b Conjugate Vaccine (Hib) market size, projected growth trends, production technologies, key applications, and end-use industries.

Haemophilus b Conjugate Vaccine (Hib) Segment by Company

Merck

GSK

Sanofi Pasteur, SA

Haemophilus b Conjugate Vaccine (Hib) Segment by Type

Inactivated Vaccine

Live Attenuated Vaccine

Haemophilus b Conjugate Vaccine (Hib) Segment by Application

Government Institution

Private Sector

Other

Haemophilus b Conjugate Vaccine (Hib) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Haemophilus b Conjugate Vaccine (Hib) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Haemophilus b Conjugate Vaccine (Hib) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Haemophilus b Conjugate Vaccine (Hib) significant trends, drivers, influence factors in global and regions.

6. To analyze Haemophilus b Conjugate Vaccine (Hib) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Haemophilus b Conjugate Vaccine (Hib) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Haemophilus b Conjugate Vaccine (Hib) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Haemophilus b Conjugate Vaccine (Hib).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Haemophilus b Conjugate Vaccine (Hib) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Haemophilus b Conjugate Vaccine (Hib) industry.

Chapter 3: Detailed analysis of Haemophilus b Conjugate Vaccine (Hib) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Haemophilus b Conjugate Vaccine (Hib) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Haemophilus b Conjugate Vaccine (Hib) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Haemophilus b Conjugate Vaccine (Hib) Industry Trends Table 2. Haemophilus b Conjugate Vaccine (Hib) Industry Drivers Table 3. Haemophilus b Conjugate Vaccine (Hib) Industry Opportunities and Challenges Table 4. Haemophilus b Conjugate Vaccine (Hib) Industry Restraints Table 5. Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Company (2021-2026) Table 7. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume Share by Company (2021-2026) Table 9. Global Haemophilus b Conjugate Vaccine (Hib) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Haemophilus b Conjugate Vaccine (Hib) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Haemophilus b Conjugate Vaccine (Hib) Key Company Manufacturing Base & Headquarters Table 12. Global Haemophilus b Conjugate Vaccine (Hib) Company, Product Type & Application Table 13. Global Haemophilus b Conjugate Vaccine (Hib) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Haemophilus b Conjugate Vaccine (Hib) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Inactivated Vaccine Table 18. Significant Companies of Live Attenuated Vaccine Table 19. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume Share by Type (2021-2026) Table 23. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume Share by Type (2027-2032) Table 24. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type (2021-2026) Table 28. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Government Institution Table 30. Significant Companies of Private Sector Table 31. Significant Companies of Other Table 32. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume Share by Application (2021-2026) Table 36. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume Share by Application (2027-2032) Table 37. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application (2021-2026) Table 41. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application (2027-2032) Table 42. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region (2021-2026) & (K Units) Table 44. Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Region (2021-2026) Table 45. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region (2027-2032) & (K Units) Table 46. Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Region (2027-2032) Table 47. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Region (2021-2026) Table 50. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Region (2027-2032) Table 52. Global Haemophilus b Conjugate Vaccine (Hib) Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Haemophilus b Conjugate Vaccine (Hib) Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2021-2026) & (K Units) Table 57. Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Country (2021-2026) Table 58. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2027-2032) & (K Units) Table 59. Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Country (2027-2032) Table 60. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Market Share by Country (2021-2026) Table 62. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Market Share by Country (2027-2032) Table 64. Merck Company Information Table 65. Merck Business Overview Table 66. Merck Haemophilus b Conjugate Vaccine (Hib) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Merck Haemophilus b Conjugate Vaccine (Hib) Product Portfolio Table 68. Merck Recent Development Table 69. GSK Company Information Table 70. GSK Business Overview Table 71. GSK Haemophilus b Conjugate Vaccine (Hib) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. GSK Haemophilus b Conjugate Vaccine (Hib) Product Portfolio Table 73. GSK Recent Development Table 74. Sanofi Pasteur, SA Company Information Table 75. Sanofi Pasteur, SA Business Overview Table 76. Sanofi Pasteur, SA Haemophilus b Conjugate Vaccine (Hib) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Sanofi Pasteur, SA Haemophilus b Conjugate Vaccine (Hib) Product Portfolio Table 78. Sanofi Pasteur, SA Recent Development Table 79. Key Raw Materials Table 80. Raw Materials Key Suppliers Table 81. Haemophilus b Conjugate Vaccine (Hib) Distributors List Table 82. Haemophilus b Conjugate Vaccine (Hib) Customers List Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. Haemophilus b Conjugate Vaccine (Hib) Product Image Figure 2. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Haemophilus b Conjugate Vaccine (Hib) Sales (2021-2032) & (K Units) Figure 5. Global Haemophilus b Conjugate Vaccine (Hib) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Haemophilus b Conjugate Vaccine (Hib) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Inactivated Vaccine Image Figure 10. Live Attenuated Vaccine Image Figure 11. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume Share by Type (2021-2032) Figure 14. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type (2021-2032) Figure 17. Government Institution Image Figure 18. Private Sector Image Figure 19. Other Image Figure 20. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume Share by Application (2021-2032) Figure 23. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application (2021-2032) Figure 26. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Haemophilus b Conjugate Vaccine (Hib) Sales Value (2021-2032) & (US$ Million) Figure 31. North America Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Haemophilus b Conjugate Vaccine (Hib) Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Haemophilus b Conjugate Vaccine (Hib) Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Haemophilus b Conjugate Vaccine (Hib) Sales Value (2021-2032) & (US$ Million) Figure 37. South America Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Haemophilus b Conjugate Vaccine (Hib) Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Haemophilus b Conjugate Vaccine (Hib) Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Haemophilus b Conjugate Vaccine (Hib) Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Inactivated Vaccine
  • Live Attenuated Vaccine
Applications
  • Government Institution
  • Private Sector
  • Other
Companies covered
  • Merck
  • GSK
  • Sanofi Pasteur, SA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value (2021-2032)
  4. 1.2.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume (2021-2032)
  5. 1.2.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Haemophilus b Conjugate Vaccine (Hib) Market Dynamics
  1. 2.1 Haemophilus b Conjugate Vaccine (Hib) Industry Trends
  2. 2.2 Haemophilus b Conjugate Vaccine (Hib) Industry Drivers
  3. 2.3 Haemophilus b Conjugate Vaccine (Hib) Industry Opportunities and Challenges
  4. 2.4 Haemophilus b Conjugate Vaccine (Hib) Industry Restraints
3 Haemophilus b Conjugate Vaccine (Hib) Market by Company
  1. 3.1 Global Haemophilus b Conjugate Vaccine (Hib) Company Revenue Ranking in 2025
  2. 3.2 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Company (2021-2026)
  3. 3.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Company (2021-2026)
  4. 3.4 Global Haemophilus b Conjugate Vaccine (Hib) Average Price by Company (2021-2026)
  5. 3.5 Global Haemophilus b Conjugate Vaccine (Hib) Company Ranking (2024-2026)
  6. 3.6 Global Haemophilus b Conjugate Vaccine (Hib) Company Manufacturing Base and Headquarters
  7. 3.7 Global Haemophilus b Conjugate Vaccine (Hib) Company Product Type and Application
  8. 3.8 Global Haemophilus b Conjugate Vaccine (Hib) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Haemophilus b Conjugate Vaccine (Hib) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Haemophilus b Conjugate Vaccine (Hib) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Haemophilus b Conjugate Vaccine (Hib) Market by Type
  1. 4.1 Haemophilus b Conjugate Vaccine (Hib) Type Introduction
  2. 4.1.1 Inactivated Vaccine
  3. 4.1.2 Live Attenuated Vaccine
  4. 4.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Type
  5. 4.2.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Type
  9. 4.3.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type (2021-2032)
5 Haemophilus b Conjugate Vaccine (Hib) Market by Application
  1. 5.1 Haemophilus b Conjugate Vaccine (Hib) Application Introduction
  2. 5.1.1 Government Institution
  3. 5.1.2 Private Sector
  4. 5.1.3 Other
  5. 5.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Application
  6. 5.2.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Application
  10. 5.3.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application (2021-2032)
6 Haemophilus b Conjugate Vaccine (Hib) Regional Sales and Value Analysis
  1. 6.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region (2021-2032)
  3. 6.2.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region: 2021-2026
  4. 6.2.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region (2027-2032)
  5. 6.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Region (2027-2032)
  9. 6.5 Global Haemophilus b Conjugate Vaccine (Hib) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Haemophilus b Conjugate Vaccine (Hib) Sales Value (2021-2032)
  12. 6.6.2 North America Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Haemophilus b Conjugate Vaccine (Hib) Sales Value (2021-2032)
  15. 6.7.2 Europe Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Haemophilus b Conjugate Vaccine (Hib) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Haemophilus b Conjugate Vaccine (Hib) Sales Value (2021-2032)
  21. 6.9.2 South America Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Haemophilus b Conjugate Vaccine (Hib) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Country, 2025 VS 2032
7 Haemophilus b Conjugate Vaccine (Hib) Country-level Sales and Value Analysis
  1. 7.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2021-2032)
  4. 7.3.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2021-2026)
  5. 7.3.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2027-2032)
  6. 7.4 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Haemophilus b Conjugate Vaccine (Hib) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Haemophilus b Conjugate Vaccine (Hib) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Haemophilus b Conjugate Vaccine (Hib) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Haemophilus b Conjugate Vaccine (Hib) Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Haemophilus b Conjugate Vaccine (Hib) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GSK Haemophilus b Conjugate Vaccine (Hib) Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Sanofi Pasteur, SA
  14. 8.3.1 Sanofi Pasteur, SA Company Information
  15. 8.3.2 Sanofi Pasteur, SA Business Overview
  16. 8.3.3 Sanofi Pasteur, SA Haemophilus b Conjugate Vaccine (Hib) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Pasteur, SA Haemophilus b Conjugate Vaccine (Hib) Product Portfolio
  18. 8.3.5 Sanofi Pasteur, SA Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Haemophilus b Conjugate Vaccine (Hib) Value Chain Analysis
  2. 9.1.1 Haemophilus b Conjugate Vaccine (Hib) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Haemophilus b Conjugate Vaccine (Hib) Sales Mode & Process
  6. 9.2 Haemophilus b Conjugate Vaccine (Hib) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Haemophilus b Conjugate Vaccine (Hib) Distributors
  9. 9.2.3 Haemophilus b Conjugate Vaccine (Hib) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst